Research Topics
Genomes and GenesSpecies | Harold L DauermanSummaryAffiliation: University of Vermont Country: USA Publications
| Collaborators
|
Detail Information
Publications
Use of the invasive management strategy for patients with non-Q-wave myocardial infarction: an observational database report from the Worcester Heart Attack StudyHarold L Dauerman
Cardiac Unit, University of Vermont College of Medicine, Burlington, VT 05401, USA
Am Heart J 143:1033-9. 2002..However, the broader use and impact of the invasive management approach has not been established for patients with acute coronary syndromes beyond the relatively narrow patient populations studied in randomized, clinical trials...- Vascular closure devices: the second decadeHarold L Dauerman
Division of Cardiology, University of Vermont College of Medicine, Burlington, Vermont 05401, USA
J Am Coll Cardiol 50:1617-26. 2007..Challenges in the second decade of VCD experience will include performing definitive randomized trials, evaluating outcomes in higher-risk patients, and developing more ideal closure devices... - Bleeding complications in patients with anemia and acute myocardial infarctionHarold L Dauerman
Division of Cardiology, University of Vermont, Burlington, VT, USA
Am J Cardiol 96:1379-83. 2005..89, 95% confidence interval 0.64 to 1.23). In conclusion, these findings suggest that bleeding complications are a potential mechanism for increased mortality among patients who have anemia and present with AMI... - Bleeding avoidance strategies. Consensus and controversyHarold L Dauerman
Division of Cardiology, University of Vermont College of Medicine, 111 Colchester Avenue, Burlington, VT 05401, USA
J Am Coll Cardiol 58:1-10. 2011..Furthermore, we focus on areas of controversy for selected modalities in order to define key areas warranting cautious clinical approaches and the need for future randomized clinical trials in this area... - Current incidence and clinical outcomes of bivalirudin administration among patients undergoing primary coronary intervention for stent thrombosis elevation acute myocardial infarctionHarold L Dauerman
University of Vermont College of Medicine, Fletcher Allen Health Care, Burlington, Vermont 05401, USA
Coron Artery Dis 18:141-8. 2007..Current utilization and outcomes of antithrombotic agents for primary percutaneous coronary intervention, including bivalirudin, have not been defined... - Challenges in oral antiplatelet therapy: ST-segment elevation myocardial infarctionHarold L Dauerman
University of Vermont College of Medicine, Cardiac Unit, Fletcher Allen Health Care, 111 Colchester Avenue, Burlington, VT 05401, USA
Am J Cardiol 104:39C-43C. 2009..Maximizing the efficacy and safety of long-term oral antiplatelet therapy requires individualization of therapy, heightened clinical judgement, and caution... - Bridging the gap between clinical trials of antiplatelet therapies and applications among elderly patientsHarold L Dauerman
University of Vermont College of Medicine, Burlington, VT 05403, USA
Am Heart J 159:508-517.e1. 2010..Considerations for future trial designs, registries, and analyses of existing data are highlighted to better guide clinicians toward the optimal management of this rapidly growing, high-risk group... - Outcomes of percutaneous coronary intervention among elderly patients in cardiogenic shock: a multicenter, decade-long experienceHarold L Dauerman
University of Vermont College of Medicine, Burlington, Vermont, USA
J Invasive Cardiol 15:380-4. 2003..The objective of this study was to determine the characteristics and hospital mortality rate for elderly patients in cardiogenic shock undergoing emergent percutaneous coronary intervention (PCI)... - Revascularization, stenting, and outcomes of patients with acute myocardial infarction complicated by cardiogenic shockHarold L Dauerman
University of Vermont College of Medicine, Fletcher Allen Health Care, Burlington, Vermont 05401, USA
Am J Cardiol 90:838-42. 2002..In this multinational registry study, coronary stenting was the most powerful independent predictor of hospital survival... - Activated clotting times in the setting of eptifibatide use during percutaneous coronary interventionHarold L Dauerman
Cardiac Unit, University of Vermont College of Medicine, Burlington, Vermont 05401, USA
J Thromb Thrombolysis 13:127-32. 2002..The impact of the short acting glycoprotein (GP) IIb-IIIa inhibitor, eptifibatide, on ACT measurements has not been studied... - Approaches to restenosis: mechanical and pharmacological strategies. OverviewHarold L Dauerman
University of Vermont/Fletcher Allen Health Care, Burlington, Vermont 05401, USA
Coron Artery Dis 15:303-5. 2004 - Two hour bivalirudin infusion after PCI for ST elevation myocardial infarctionPhillip R Anderson
McClure 1 Cardiology, Fletcher Allen Health Care, 111, Colchester Ave, Burlington, VT 05401, USA
J Thromb Thrombolysis 31:401-6. 2011..7% of STEMI patients. In conclusion, prolonging bivalirudin for 2 h after STEMI PCI may be a promising method to alleviate acute stent thrombosis risk without losing the bleeding complication benefit of the bivalirudin strategy... - Extravascular closure for patients with high-risk femoral anatomyMitchell N Rashid
Division of Cardiology, Department of Medicine, University of Vermont College of Medicine, Burlington, VT 05401, USA
J Invasive Cardiol 20:328-32. 2008..However, VCD studies have excluded patients with high-risk femoral artery anatomy; we examined the safety and efficacy of clip-based extravascular closure in this high-risk group... - Relation of leukocytosis to C-reactive protein and interleukin-6 among patients undergoing percutaneous coronary interventionProspero B Gogo
Division of Cardiology, University of Vermont College of Medicine, Burlington, Vermont, USA
Am J Cardiol 96:538-42. 2005..78, 95% confidence interval 1.07 to 13.3, p = 0.04). In conclusion, in patients with troponin I negative coronary syndromes, a pre-PCI elevation in the WBC count reflected cytokine-mediated inflammation... - Comparison of inflammatory markers in patients with diabetes mellitus versus those without before and after coronary arterial stentingAtul Aggarwal
Cardiology Unit, University of Vermont, Burlington, Vermont 05401, USA
Am J Cardiol 92:924-9. 2003..Thus, patients with and without diabetes exhibit different inflammatory responses to stenting, reflecting the lower preprocedural inflammation in those without diabetes versus those with diabetes... - Systemic inflammation after drug-eluting stent placementProspero B Gogo
Division of Cardiology, University of Vermont College of Medicine, 111 Colchester Avenue, Burlington, Vermont 05401, USA
J Thromb Thrombolysis 19:87-92. 2005..CONCLUSIONS: The inflammatory response to PCI appears similar in those treated with DES and BMS. Accordingly, the reduction in restenosis after DES is likely not mediated by attenuation of the systemic markers CRP, IL-1Ra, or IL-6... - Increased coronary arterial release of interleukin-1 receptor antagonist and soluble CD40 ligand indicative of inflammation associated with culprit coronary plaquesAtul Aggarwal
Cardiac Unit, University of Vermont College of Medicine, Burlington, Vermont 05401, USA
Am J Cardiol 93:6-9. 2004.... - Increased expression of platelet P-selectin and formation of platelet-leukocyte aggregates in blood from patients treated with unfractionated heparin plus eptifibatide compared with bivalirudinFriederike K Keating
Cardiology Unit, Department of Medicine, University of Vermont Fletcher Allen Health Care, 111 Colchester Avenue, Burlington, VT 05401, USA
Thromb Res 118:361-9. 2006.... - Increase in interleukin-6 in the first hour after coronary stenting: an early marker of the inflammatory responseAtul Aggarwal
Cardiology Unit, University of Vermont College of Medicine, Burlington, VT 05401, USA
J Thromb Thrombolysis 15:25-31. 2003..21). CONCLUSIONS: In patients undergoing coronary stenting, increase in IL-6 can be detected 1 hour after PCI, and thus IL-6 may be an early initiator of the systemic inflammatory response to stenting... - Osteoprotegerin is not associated with angiographic coronary calcificationProspero B Gogo
Division of Cardiology, University of Vermont College of Medicine, Burlington, VT 05401, USA
J Thromb Thrombolysis 22:177-83. 2006..After PCI, osteoprotegerin decreased while proinflammatory cytokines increased, which may be consistent with a counterregulatory role for osteoprotegerin... - Angiographic predictors of vascular complications among women undergoing cardiac catheterization and interventionBina Ahmed
Division of Cardiology, McClure 1, University of Vermont Fletcher Allen Health Care, 111 Colchester Avenue, Burlington VT 05401, USA
J Invasive Cardiol 22:512-6. 2010..Bleeding and vascular complications remain more common in women than men undergoing invasive cardiovascular procedures. We determined the role of femoral angiographic variables in risk-stratifying women for vascular complications... - Significantly improved vascular complications among women undergoing percutaneous coronary intervention: a report from the Northern New England Percutaneous Coronary Intervention RegistryBina Ahmed
Division of Cardiology, University of Vermont College of Medicine, Burlington, VT, USA
Circ Cardiovasc Interv 2:423-9. 2009..Although the overall incidence of percutaneous coronary intervention (PCI)-related bleeding/VC has declined, the impact of this decline, specifically in women, is unknown... - Changes in patterns of coronary revascularization strategies for patients with acute coronary syndromes (from the CRUSADE Quality Improvement Initiative)Prospero B Gogo
University of Vermont College of Medicine, Burlington, Vermont, USA
Am J Cardiol 99:1222-6. 2007..Long-term implications of this shift remain uncertain, especially in patients with 3VD... - Percutaneous coronary intervention for major bifurcation lesions using the simple approach: risk of myocardial infarctionEram C Chaudhry
Division of Cardiology, McClure 1, University of Vermont College of Medicine, 111 Colchester Avenue, Burlington, VT 05401, USA
J Thromb Thrombolysis 24:7-13. 2007..Recent data has suggested that simple (main vessel only) stenting is the preferred approach for patients with bifurcation lesions. We sought to determine the feasibility and outcomes of this approach in a year long inclusive registry... - Bleeding complications after contemporary pharmacoinvasive therapy for ST elevation myocardial infarctionMatthew J Gutierrez
University of Vermont College of Medicine, Burlington, VT 05401, USA
J Thromb Thrombolysis 18:187-92. 2004..Antecedent thrombolytic therapy was not a predictor of bleeding complications after PCI. CONCLUSIONS: Use of CD as part of a contemporary pharmacoinvasive strategy is associated with a low rate of major bleeding complications... - N-acetylcysteine-enhanced contrast provides cardiorenal protectionMarkus Meyer
Division of Cardiology, University of Vermont College of Medicine, Burlington, Vermont 05401, USA
JACC Cardiovasc Interv 2:215-21. 2009..We sought to evaluate the cardiac and renal effects of an N-acetylcysteine (NAC)-enhanced intracoronary radiographic contrast agent... - Recent changes in practice of elective percutaneous coronary intervention for stable anginaBina Ahmed
Division of Cardiology, University of New Mexico, Albuquerque, NM 87131, USA
Circ Cardiovasc Qual Outcomes 4:300-5. 2011..The impact of results from the COURAGE trial on clinical practice is unknown... - Frequency and safety of switching antithrombin therapy at a regional PCI centerBina Ahmed
Division of Cardiology, University of Vermont Fletcher Allen Health Care, McClure 1, 111 Colchester Avenue, Burlington, VT 05401, USA
J Thromb Thrombolysis 29:282-8. 2010.... - Complete Cypher stent fracture and migration in the ostium of the right coronary arteryJason T Bradley
Division of Cardiology and Cardiothoracic Surgery, University of Vermont College of Medicine, Burlington, VT 05401, USA
J Invasive Cardiol 19:E99-101. 2007 - Overview: drug eluting stentsHarold L Dauerman
Division of Cardiology, University of Vermont College of Medicine, Burlington, Vermont, USA
Coron Artery Dis 17:657-9. 2006 - Synergistic treatment of ST-segment elevation myocardial infarction with pharmacoinvasive recanalizationHarold L Dauerman
Department of Medicine, University of Vermont College of Medicine, Burlington 05446, USA
J Am Coll Cardiol 42:646-51. 2003.... - Comparison of effects of abciximab versus eptifibatide on C-reactive protein, interleukin-6, and interleukin-1 receptor antagonist after coronary arterial stentingAtul Aggarwal
Cardiac Unit, University of Vermont College of Medicine, 111 Colchester Avenue, Burlington, VT 05401, USA
Am J Cardiol 91:1346-9. 2003 - Detection of coronary artery stenosis using 40-channel computed tomography with multi-segment reconstructionMatthew W Watkins
Department of Cardiology, Fletcher Allen Health Care University of Vermont, Burlington, Vermont, USA
Am J Cardiol 99:175-81. 2007..In conclusion, coronary angiography using 40-channel multidetector computer tomography with multi-segment reconstruction accurately detects coronary segments and patients with obstructive CAD, with a small number of non-evaluable cases... - Genetic regulation of platelet receptor expression and function: application in clinical practice and drug developmentMarlene S Williams
Division of Cardiology, Department of Medicine, Johns Hopkins University, Baltimore, MD 21224, USA
Arterioscler Thromb Vasc Biol 30:2372-84. 2010.... - Coronary venous capture of contrast during angiographyMarkus Meyer
Division of Cardiology, College of Medicine, University of Vermont, Burlington, Vermont, USA
J Interv Cardiol 19:401-4. 2006..As an adjunct procedure in coronary angiography, VCC has the potential to significantly reduce the risk of CIN in patients at risk... - Consistent door-to-balloon times of less than 90 minutes for STEMI patients transferred for primary PCIBina Ahmed
Department of Cardiology, University of Vermont, 111 Colchester Avenue, Burlington, VT 05401, USA
J Invasive Cardiol 21:429-33. 2009..We established a streamlined STEMI protocol to allow rapid transfer of STEMI patients for primary PCI to meet the ACC D2B goal of < or = 90 minutes in at least 75% of the patients... - A novel use for a distal embolic protection device: stent retrievalPavel Guigauri
Division of Cardiology, University of Vermont College of Medicine, Fletcher Allen Health Care, 111 Colchester Avenue, Burlington, VT, 05401, USA
J Invasive Cardiol 17:183-4. 2005 - Coronary intervention without a safety netHarold L Dauerman
J Am Coll Cardiol 52:1299-301. 2008 - Comparing long-term survival of patients with multivessel coronary disease after CABG or PCI: analysis of BARI-like patients in northern New EnglandDavid J Malenka
Dartmouth Hitchcock Medical Center, Lebanon, NH 03756, USA
Circulation 112:I371-6. 2005..Our goal in this study was to compare long-term survival of MVD patients treated with CABG vs PCI in contemporary practice... - Soluble CD40 ligand is an early initiator of inflammation after coronary interventionAtul Aggarwal
Nebraska Heart Institute, Hastings, Nebraska 68901, USA
Coron Artery Dis 15:471-5. 2004..The role of soluble CD40 ligand (sCD40L) as a potential initiator of inflammation after stenting has not been described... - Endothelial dysfunction and inflammation after percutaneous coronary interventionArnon Blum
Department of Internal Medicine A, Poria Medical Center, Lower Galilee, Israel
Am J Cardiol 94:1420-3. 2004..Thus, endothelium-dependent dilation abnormalities were related to the systemic inflammatory state, whereas endothelium-independent dilation abnormalities were not related to the inflammatory status of the patient... - The effects of bivalirudin compared with those of unfractionated heparin plus eptifibatide on inflammation and thrombin generation and activity during coronary interventionFriederike K Keating
Cardiology Unit, Department of Medicine, University of Vermont Burlington, Colchester, Vermont 05446, USA
Coron Artery Dis 16:401-5. 2005.... - Clinical, procedural, and pharmacologic correlates of acute and subacute stent thrombosis: results of a multicenter case-control study with 145 thrombosis eventsMichael J Rinaldi
Beth Israel Deaconess Medical Center, Boston, MA, USA
Am Heart J 155:654-60. 2008.... - Triple antiplatelet therapy does not increase femoral access bleeding with vascular closure devicesJose E Exaire
Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
Am Heart J 147:31-4. 2004..CONCLUSIONS: In contemporary percutaneous coronary intervention practice, with appropriate patient selection, a CD can be safely utilized despite aggressive polypharmacy for procedural anticoagulation... - Percutaneous coronary intervention pharmacology: from a triangle to a squareHarold L Dauerman
J Am Coll Cardiol 51:698-700. 2008 - The early days after ST-segment elevation acute myocardial infarction: reconsidering the delayed invasive approachHarold L Dauerman
J Am Coll Cardiol 42:420-3. 2003 - Treatment of stent restenosis: moving beyond momentumHarold L Dauerman
J Am Coll Cardiol 47:2161-3. 2006